Monthly News Roundup - January 2024
First-in-Class Zelsuvmi Topical Gel Cleared for Molluscum Contagiosum
In January, the FDA cleared Zelsuvmi (berdazimer sodium 10.3%), a topical treatment for molluscum contagiosum (MC) in adults and children 1 year of age and older. Molluscum... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2024 Category: Pharmaceuticals Source Type: news
At-Home Treatment for Molluscum Contagiosum Wins FDA Approval
(MedPage Today) -- The FDA approved the first at-home topical therapy for molluscum contagiosum, a highly contagious viral skin infection that primarily affects children.
The approval of berdazimer gel 10.3% (Zelsuvmi) includes adults and children... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 8, 2024 Category: American Health Source Type: news
FDA Gives Nod to Berdazimer Gel for Molluscum Contagiosum FDA Gives Nod to Berdazimer Gel for Molluscum Contagiosum
The topical treatment is expected to be commercially available in the second half of 2024.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 6, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
FDA Approves Zelsuvmi (berdazimer topical gel) for the Treatment of Molluscum Contagiosum
SAN DIEGO--(BUSINESS WIRE) January 5, 2024 -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved Zelsuvmi™ (berdazimer topical gel, 10.3%) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 5, 2024 Category: Drugs & Pharmacology Source Type: news
Safely Treating Molluscum, a Common Skin Condition
A common skin infection that some people try to self-diagnose and treat is molluscum contagiosum. But by doing so, you run the risk of delaying the diagnosis and treatment of a potentially serious condition. The FDA has not approved any nonprescription products for the treatment of molluscum. (Source: FDA Consumer Health Information Updates)
Source: FDA Consumer Health Information Updates - August 21, 2023 Category: Consumer Health News Authors: FDA Source Type: news
FDA Approves Topical Treatment for Molluscum Contagiosum
MONDAY, July 24, 2023 -- The U.S. Food and Drug Administration has approved the topical solution Ycanth (cantharidin) for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients (aged 2 years and older).
Ycanth uses a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 24, 2023 Category: General Medicine Source Type: news
FDA Approves Topical Treatment for Molluscum Contagiosum, Ycanth
MONDAY, July 24, 2023 -- The U.S. Food and Drug Administration has approved the topical solution Ycanth (cantharidin) for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients (aged 2 years and older).
Ycanth uses a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 24, 2023 Category: General Medicine Source Type: news
First Treatment Approved for Molluscum Contagiosum
(MedPage Today) -- Topical cantharidin (Ycanth) was approved as the first treatment specifically for molluscum contagiosum, the FDA announced.
Molluscum contagiosum is a viral skin infection that affects as many as 6 million Americans, mostly... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 24, 2023 Category: Infectious Diseases Source Type: news
FDA Approves Cantharidin for Treating Molluscum Contagiosum FDA Approves Cantharidin for Treating Molluscum Contagiosum
The product is a drug-device combination that contains a formulation of cantharidin solution (0.7%), delivered topically via a single-use applicator.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 24, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
FDA Approves Ycanth (cantharidin) Topical Solution for the Treatment of Molluscum Contagiosum
WEST CHESTER, PA–Jul 21, 2023 (GLOBE NEWSWIRE)– Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 21, 2023 Category: Drugs & Pharmacology Source Type: news
Don ’t Use Products Marketed to Treat Molluscum, a Common Skin Condition
A common skin infection that some people try to self-diagnose and treat is molluscum contagiosum. But by doing so, you run the risk of delaying the diagnosis and treatment of a potentially serious condition. The FDA has not approved any products for the treatment of molluscum. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 1, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks
(MedPage Today) -- NEW ORLEANS -- Almost 40% of patients with molluscum contagiosum, some with dozens of lesions, had complete or near-complete clearance after 12 weeks of nitric oxide-releasing gel, the largest-ever randomized trial of the skin... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 23, 2023 Category: Dermatology Source Type: news
FDA Accepts Application for Topical Molluscum Treatment FDA Accepts Application for Topical Molluscum Treatment
If approved, berdazimer gel would be the first FDA-approved prescription product for molluscum contagiosum in the United States.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 8, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
WEST CHESTER, PA– February 27, 2023 (GLOBE NEWSWIRE)– Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 27, 2023 Category: Drugs & Pharmacology Source Type: news
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum
Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone
WEST CHESTER, PA– January 24, 2023 (GLOBE NEWSWIRE)– Verrica... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 24, 2023 Category: Drugs & Pharmacology Source Type: news
